{"id":610497,"date":"2026-02-23T13:26:13","date_gmt":"2026-02-23T13:26:13","guid":{"rendered":"https:\/\/www.europesays.com\/us\/610497\/"},"modified":"2026-02-23T13:26:13","modified_gmt":"2026-02-23T13:26:13","slug":"novo-next-generation-obesity-shot-falls-short-of-lilly-rival","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/610497\/","title":{"rendered":"Novo Next-Generation Obesity Shot Falls Short of Lilly Rival"},"content":{"rendered":"<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody___5jDr\" data-component=\"paragraph\">Novo Nordisk A\/S\u2019s next-generation obesity shot delivered less weight loss than Eli Lilly &amp; Co.\u2019s rival blockbuster in yet another blow to the Danish company\u2019s attempts to regain lost ground in the weight-loss market.<\/p>\n<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody___5jDr\" data-component=\"paragraph\">People treated with a standard dose of Novo\u2019s CagriSema in a <a href=\"https:\/\/www.bloomberg.com\/news\/terminal\/TAWNV3TP3SHS\" class=\"media-ui-Link_link-tVkXhPLPofs- whitespace-normal\" target=\"_blank\" rel=\"noopener nofollow\" data-component=\"link\">trialBloomberg Terminal<\/a> achieved 20.2% weight loss after 84 weeks, compared with 23.6% for Lilly\u2019s tirzepatide. Novo\u2019s shares plunged as much as 16.5% in Copenhagen on Monday, while Lilly shares rose as much as 4.2% in premarket US trading.<\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk A\/S\u2019s next-generation obesity shot delivered less weight loss than Eli Lilly &amp; Co.\u2019s rival blockbuster in&hellip;\n","protected":false},"author":3,"featured_media":610498,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[6],"tags":[64,17010,392,262114,1230,62222,262113,62224,262112,170635,62221,15008,67,132,68],"class_list":["post-610497","post","type-post","status-publish","format-standard","has-post-thumbnail","category-business","tag-business","tag-chief-executive-officer","tag-culture","tag-danske-bank-a-s","tag-drugs","tag-eli-lilly-co","tag-health-invest","tag-industries","tag-maziar-mike-doustdar","tag-metsera-inc","tag-novo-nordisk-a-s-b","tag-pfizer-inc","tag-united-states","tag-unitedstates","tag-us"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/116120176899846126","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/610497","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=610497"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/610497\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/610498"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=610497"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=610497"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=610497"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}